Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice action here. Any real buying pressure comes in and this one will move very quick.
I was watching this all week and right before I pull the trigger someone drove it up to .019 they wanted those shares bad. HDSN MM has this boxed in. I picked up the .012 's today, and planning on adding more. This will run so fast u wont be able to think of a price to jump in at. lol
Good Luck Everyone
.10-.30 range is coming
From DEF 14C filing issued 8/16/10 regarding Beneficial Ownership:
Kevan M. Casey - 5,279,682 shares 22.3%
KM Casey No. 1, LTD. (1) - 12,988,707 shares 54.8%
Silver Star Holding (2) - 1,139,996 shares 4.8%
J. Leonard Ivins (3) - 861,875 shares 3.6%
That totals 20.3 million shares post split. If 23.7 million shares will be outstanding, the float will be only 3.5 million shares with 85% insider ownership. This could be a monster after the 9/7/10 post split date.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7415261
Read: according to you, the O/S is 23M, which mean PPS could be .76 ($17500000/23M). Once name change complete I think company might do forward split) drilling and find oil mean OCOL will be big, I think some loading up slowly..Oil prices up big time, Easy .1 soon in my opinion. This move big and you cannot load big order without pps move up big, the float so small, soon with name change and prs you might see .5 in my opinion, buy and hold and set tight once this start moving will be like %1000 move
float very low, soon to start drill, I think soon share price .1 will be there, hold. Once little buying pressure come watch .1 get there fast
OCOL .0105 x .0125
lol, i'll take it:)
Does this O/S mean the R/S mentioned in the 10-Q already happened?
Ah PR about name change to Bering Exploration and LOI for up to 5m barrels(No deal yet). They would get 5% interest. @ even $70 per barrel= $17,500,000. Only 23m O/S as of Aug 16th 10-Q Great share structure and news if it comes to fruition. One to radar for sure.
Is this going to be the new company?
http://www.manta.com/ic/mt61hsg/ca/bering-exploration-company-ulc
Careful to on this one looks like someones been loading up just waiting to dump on this
Wow Milk it does a body good
why the price drop yesterday? and jump today? is something up? did they finally release the report on the land analysis? anyone know?.....
Sure does look that way. Without any action from people here or anyother site. Looks like just me and you.
Oh well when it picks up who knows what can happen.
Rick
All orders continuing to hit the ask at .021-.022 with the bid at .020. Shares being accumulated, I like the looks of this!
There will be a PR soon enough regarding its possible lease acquisition:
"The company anticipates beginning the field study within the next two weeks which includes evaluating drilling locations and possible re-entries. Upon a successful outcome of the field study the company will begin the lease acquisition phase."
Sure looks that way more vol would help move this fast. A good PR won't hurt.
All orders the last two days have been hitting the ask, looks like some accumulation going on.
L2 snapshot 1:30pm
Notice all the buys are hitting the ask, none at the bid so far.
Buying pressure building, looking good.
Looks like this may run soon.
Oncolin Identifies Largest Prospect to Date with a Potential of 3,000,000 Gross Barrels of Oil and 30 Bcf of Gas Reserves
Monday April 6, 2009, 4:15 pm EDT
HOUSTON--(BUSINESS WIRE)--Oncolin (OTC: OCOL - News) announces that it has identified its largest prospect to date located in Cameron Parish, Louisiana with a potential of 3,000,000 gross barrels of oil reserves and 30Bcf of natural gas reserves. The company anticipates beginning the field study within the next two weeks which includes evaluating drilling locations and possible re-entries. Upon a successful outcome of the field study the company will begin the lease acquisition phase.
The company is continuing to build its prospect inventory and focus on developing or “rehabbing” fields that provide the best economics taking the current oil & gas prices into consideration and also the ability to procure the necessary leases. The company will prioritize the leasing and development of these fields after conducting field studies and securing the necessary funding to proceed.
It's moving today
Watching this here -- could be a good move coming
Stock is looking good, check it out has some value
Start Trading, stock looks good, volume up;
anyone have anymore info on OCOL?
Oncolin Therapeutics Announces Its New 'Super Cell Blocker', ONC-127, Has Shown Effectiveness in Treating Cancer
--------------------------------------------------------------------------------
Tue May 13 16:05:01 2008 EDT
HOUSTON, May 13, 2008 (BUSINESS WIRE) --
Oncolin Therapeutics, Inc., (OTCBB:OCOL) announces that its new
Super Cell Blocker, ONC-127, has been effective in treating animals
that have been implanted with human tumors in their brains. This
technology has extended the life of animals in a preclinical
environment.
The Super Cell Blocker, ONC-127, drug candidate is a major
breakthrough in inhibiting a process known as glycolysis which
"starves the tumor" by blocking its ability to provide energy for the
cell to live. The founding scientists have designed a drug that passes
through the Blood Brain Barrier (BBB) which is the brain's security
mechanism that stops most other drugs from reaching the brain in order
to target the brain tumor and is also selectively taken up by brain
tumor cells. This technology is also applicable to other cancers that
have a high sugar uptake such as breast and pancreatic cancers.
This technology is covered under Oncolin's recent exclusive option
to license from The University of Texas M.D. Anderson Cancer Center
which is one of the world's leading cancer treatment facilities.
About Oncolin Therapeutics, Inc.
Headquartered in Houston, Texas, Oncolin Therapeutics, Inc. is a
publicly traded biopharmaceutical company that engages in the
discovery, development and commercialization of novel selective
anticancer therapies. Additional information about Oncolin can be
found on the web at www.oncolinthera.com.
Safe Harbor Statement
This press release contains statements that may constitute
forward-looking statements, including the company's ability to
successfully acquire and develop technologies that are and may be
acquired. These statements are based on current expectations and
assumptions and involve a number of uncertainties and risks that could
cause actual results to differ materially from those currently
expected. For additional information about Oncolin's future business
and financial results, refer to Oncolin's Quarterly Report on Form
10-QSB for the quarter ended December 31, 2007 and Annual Report on
Form 10-KSB for the year ended March 31, 2007. Oncolin Therapeutics
undertakes no obligation to update any forward-looking statement that
may be made from time to time by or on behalf of the company, whether
as a result of new information, future events or otherwise.
SOURCE: Oncolin Therapeutics, Inc.
Oncolin Therapeutics, Inc., Houston
J. Leonard Ivins, 832-426-7909
Investors@oncolinthera.com
Copyright Business Wire 2008
OCOL: Signs Sponsored Research Agreement with the University of Texas
--------------------------------------------------------------------------------
Tue Jun 10 09:11:39 2008 EDT
Ridgeland, MS, JUN 10, 2008 (EventX/Knobias.com via COMTEX News Network) --
By Jay Everitt, jeveritt@knobias.com
Oncolin Therapeutics, Inc. (OCOL) announced that it has signed a sponsored
research agreement with The University of Texas M. D. Anderson Cancer Center (UTMDACC)
in Houston, Texas to support work in the laboratory of Prof. Waldemar Priebe. This
new sponsored research will focus on the development of a new novel class of compounds
that inhibit glycolysis, the metabolic pathway essential to the survival of many
human tumors. The company will have a right to an exclusive license to any new patents
derived from this research as the company expands its support of Dr. Priebe's drug
discovery and development efforts. This sponsored research will initially focus
on evaluation of the selected lead compounds with the goal of identifying a superior
inhibitor of glycolysis that potently blocks tumor growth.
KNOBIAS DISCLAIMER: All statements made in this article were made by the
Company and do not in any way reflect the opinions of Knobias. Knobias is not a
registered broker-dealer, nor investment advisor, and does not endorse or recommend
any securities mentioned. This story is provided for informational purposes only
and is not intended for trading purposes. Knobias shall not be liable for any actions
taken in reliance of any information provided herein. Republication or redistribution
of Knobias content is expressly prohibited without prior written consent of Knobias.com,
LLC.
ABOUT KNOBIAS: Knobias is a premier financial information provider of trading
and investing data covering all U.S. equities for investors and security professionals.
Knobias is best described by its three major components: Real-time desktop applications
providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands
of real-time news stories, alerts and documents daily; Knobias fundamentals providing
a comprehensive database of fundamental research information.
If your company wishes to participate in the EventX newswire, please contact
Knobias: http://www.knobias.com
Knobias.com, LLC
601-978-3399
601-978-3675
info@knobias.com
www.knobias.com/cmtx
Copyright 2004 Knobias.com, LLC, All rights reserved.
These are my opinions only. Buying stocks is risky. Play only with money you are prepared to lose!
Followers
|
4
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
82
|
Created
|
06/04/08
|
Type
|
Free
|
Moderators |
Oncolin is currently engaged in the business of indentifying, evaluating, developing and acquiring potential natural gas and oil wells while researching new methods of clean and renewable energy production. The company will initially focus on acquiring older fields where it can utilize modern techniques to re-establish or enhance production. Oncolin will continue to oversee its minority ownership in Intertech Bio, a biopharmaceutical company that engages in the discovery, development and commercialization of novel selective anticancer therapies. Additional information about Oncolin can be found on the web at www.oncolinthera.com
Recent New
OCOL changed to BERX on Dec 15th 2010
HOUSTON, Nov. 30, 2010 /PRNewswire via COMTEX/ -- Bering Exploration, Inc., (Pink Sheets: OCOL) announced today that its South Texas prospect has tested positive for oil in its initial test phase. This well was drilled to a depth of approximately 10,000 feet to test the Oligocene Frio trend and the initial test has proven that one of the lower zones has tested positive for oil. Further testing is required to determine if this zone will be commercially viable. This prospect originally had potential gross reserves of 5,000,000 barrels of oil and 46 BCF of natural gas. Bering's interest is a 5% working interest after pay out in this prospect.
The company recently announced that it has entered into a Letter of Intent to participate in a new prospect located in the Gulf Coast area that has potential gross reserves of 120 BCF of natural gas and up to 10 million barrels of oil. Based upon recent prices this equates to a total of $1.3 billion dollars in potential gross revenue of which Bering's working interest would be 2.5% or $23 million, or $0.99 per share, over the life of the prospect. There is no guarantee that this prospect will be successful or that these numbers will be achieved due to production and/or price fluctuations.
"We believe that these initial test results confirm our strategy of seeking out low risk drilling opportunities." stated Steven Plumb, VP of Finance of Bering. "Our recent Letter of Intent in the Gulf Coast area is another example of this strategy."
About Bering Exploration, Inc.
Headquartered in Houston, Texas, Bering Exploration, Inc. is an independent oil and natural gas company that focuses on indentifying, evaluating, developing and acquiring potential natural gas and oil wells in the Gulf Coast onshore region. Additional information about Bering can be found on the web at www.beringexplore.com.
BERX is Fully Reporting OTCQB
Pink Sheets Link http://www.otcmarkets.com/stock/BERX/company-info
Transfer Agent
(480) 481-3940
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |